Bier J, Benders P, Bitter K, Wenzel M
J Maxillofac Surg. 1979 Feb;7(1):32-40. doi: 10.1016/s0301-0503(79)80008-9.
In tumour-free and tumour-bearing mice the body clearance and organ distribution of 57Co-BLM was measured at different time intervals after iv., sc., and it. administration of the drug. No significant difference could be demonstrated in body clearance following different doses and routes of application of labelled BLM in tumour-free and tumour-bearing mice. The organ distribution studies showed higher concentrations following iv. compared to sc. or it. of 57Co-BLM; however, the activity in the ipsilateral injection sites was significantly increased after sc. and it. injection. In tumour-bearing mice the activity in the lymph nodes draining injection site was as high as that seen in the draining lymph nodes following iv. injection. However, on the contralateral side, the lymph node concentration was significantly reduced after it. injection. These results indicate on the basis or organ distribution of 57Co-BLM a rational basis for it. treatment of malignant tumours.
在无瘤和荷瘤小鼠中,于静脉注射、皮下注射和瘤内注射药物后的不同时间间隔测量了57Co-BLM的体内清除率和器官分布。在无瘤和荷瘤小鼠中,给予不同剂量和不同给药途径的标记博来霉素后,体内清除率无显著差异。器官分布研究显示,静脉注射后57Co-BLM的浓度高于皮下注射或瘤内注射;然而,皮下注射和瘤内注射后同侧注射部位的活性显著增加。在荷瘤小鼠中,注射部位引流淋巴结的活性与静脉注射后引流淋巴结中的活性一样高。然而,在对侧,瘤内注射后淋巴结浓度显著降低。基于57Co-BLM的器官分布,这些结果为其治疗恶性肿瘤提供了合理依据。